1.46
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.44
Offen:
$1.44
24-Stunden-Volumen:
1.83M
Relative Volume:
0.70
Marktkapitalisierung:
$530.56M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.825
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
-3.95%
1M Leistung:
+26.96%
6M Leistung:
+175.47%
1J Leistung:
-18.44%
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Vergleichen Sie LXRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
LXRX
Lexicon Pharmaceuticals Inc
|
1.46 | 541.46M | 1.21M | -177.12M | -162.37M | -0.80 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
2023-03-07 | Eingeleitet | Jefferies | Hold |
2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
2019-07-29 | Herabstufung | Stifel | Buy → Hold |
2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
2018-07-31 | Bestätigt | Stifel | Buy |
2018-02-23 | Herabstufung | Needham | Buy → Hold |
2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
2017-03-01 | Bestätigt | Wedbush | Outperform |
2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
2016-08-05 | Bestätigt | Wedbush | Outperform |
2016-08-02 | Eingeleitet | Citigroup | Buy |
2016-03-02 | Bestätigt | Wedbush | Outperform |
2015-11-09 | Bestätigt | Wedbush | Outperform |
2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit - The Manila Times
Short interest data insights for Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & AI Enhanced Trading Signals - newser.com
Is Lexicon Pharmaceuticals Inc. stock attractive for hedge fundsWeekly Loss Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Lexicon Pharmaceuticals Inc. building a consolidation baseMarket Sentiment Summary & Reliable Price Action Trade Plans - newser.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8% HigherWhat's Next? - MarketBeat
Lexicon Pharmaceuticals' (LXRX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 6.3%Time to Sell? - MarketBeat
Lexicon (LXRX) Engages in Policy Discussion to Tackle Chronic Pa - GuruFocus
Lexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain Management - Quiver Quantitative
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - MarketScreener
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People With Chronic Pain - 富途牛牛
Detecting price anomalies in Lexicon Pharmaceuticals Inc. with AIEarnings Beat & Intraday High Probability Alerts - newser.com
Can you recover from losses in Lexicon Pharmaceuticals Inc.2025 Analyst Calls & Safe Entry Point Identification - newser.com
Is Lexicon Pharmaceuticals Inc. a candidate for recovery playPortfolio Value Summary & Consistent Income Trade Recommendations - newser.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Is Lexicon Pharmaceuticals Inc. stock bottoming out2025 Risk Factors & Weekly Watchlist for Consistent Profits - newser.com
What’s the recovery path for long term holders of Lexicon Pharmaceuticals Inc.Portfolio Return Summary & Long-Term Capital Growth Ideas - newser.com
Smart tools for monitoring Lexicon Pharmaceuticals Inc.’s price actionGap Up & High Accuracy Investment Signals - newser.com
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Affordable Trading Portfolio - earlytimes.in
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28% - simplywall.st
Lexicon Pharmaceuticals, Inc. $LXRX Stake Reduced by Goldman Sachs Group Inc. - MarketBeat
What analysts say about Lexicon Pharmaceuticals Inc stockContrarian Investment Ideas & Big Gains Low Budget - earlytimes.in
Lexicon reports FDA's decision to extend review period for Zynquista - MSN
Lexicon Pharmaceuticals, Inc. $LXRX Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes - MarketScreener
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Lexicon awaits FDA feedback on diabetes drug application in Q4 By Investing.com - Investing.com Australia
Lexicon awaits FDA feedback on diabetes drug application in Q4 - Investing.com
Lexicon Pharmaceuticals (LXRX) Faces FDA Review Extension for Zy - GuruFocus
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):